Summary: Humacyte Inc. reported Phase 3 V012 clinical data showing that its acellular tissue engineered vessel (ATEV) provided longer catheter-free intervals and a lower infection rate for women on dialysis versus the current standard, arteriovenous fistula (AV fistula). The results were presented at the Society for Vascular Surgerys Vascular Annual Meeting in Boston and coincided with a near 3% rise in the companys shares on the session.
The V012 study compared women who received Humacytes ATEV to women who underwent AV fistula creation. Over the first year following intervention, women treated with the ATEV averaged 220 catheter-free days, while those who received an AV fistula averaged 129 catheter-free days. That difference was statistically significant, with a reported p-value of 0.00070.
Infection rates also favored the ATEV cohort. The study reported approximately 6 infections per 100 patient years in the ATEV group compared with roughly 23 infections per 100 patient years among women treated with AV fistula.
Secondary efficacy measures in the trial reinforced the primary findings. At six months, catheter-free days averaged 88 for ATEV recipients and 32 for those with AV fistula. Functional patency measured over 12 months averaged 250 days for ATEV and 152 days for AV fistula.
Safety profiles were described as comparable between groups. When adjusted for patient years of exposure, serious adverse events averaged 1.73 for the ATEV group and 4.77 for the AV fistula group.
Following the presentation of these V012 results, Humacyte indicated plans to submit a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration in the second half of 2026. The planned target indication specified for the filing is adult patients with end-stage kidney disease who are at increased risk of AV fistula maturation failure.
Key takeaways
- ATEV produced an average of 220 catheter-free days over 12 months versus 129 days for AV fistula in women on dialysis, with statistical significance (p = 0.00070).
- Infection incidence was lower in the ATEV group (about 6 per 100 patient years) compared with AV fistula (about 23 per 100 patient years).
- Humacyte expects to file a supplemental BLA in the second half of 2026 for a targeted indication in adults with end-stage kidney disease at increased risk of AV fistula maturation failure.
Risks and uncertainties
- Regulatory timing and outcome - the company plans an sBLA filing in H2 2026, but the article does not provide any information on the likelihood, timing, or potential outcomes of regulatory review.
- Comparative safety and long-term durability - while safety was described as comparable and serious adverse events were lower for ATEV when adjusted for patient years, long-term outcomes beyond the reported follow-up are not provided in the data referenced.
- Market and clinical adoption - the article does not address adoption rates, clinician preferences, or payer coverage, which could affect uptake even if regulatory approval is obtained.
Overall, the V012 Phase 3 results presented in Boston show statistically significant improvements on several efficacy measures for Humacytes ATEV versus AV fistula in women on dialysis, along with a favorable infection profile and comparable safety when adjusted for exposure. The companys next stated regulatory step is an sBLA submission to the FDA during the second half of 2026 for a narrowly defined target population.